Outlook

  • Outlook |

    We have the science to make new antimalarials, say Robert Ridley and Yeya Toure, but we need better mechanisms and resources to develop drugs and deliver them.

    • Robert Ridley
    •  & Yeya Toure
  • Outlook |

    In Africa, where malaria hits hardest, scientists are crying out for countries to take matters into their own hands, says Declan Butler.

    • Declan Butler
  • Outlook |

    What makes the Mesa so attractive to pharmaceutical companies? Paul Smaglik investigates.

    • Paul Smaglik
  • Outlook |

    Scientists need help to make their entrepreneurial dreams come true. Jonathan Knight talks to the experts.

    • Jonathan Knight
  • Outlook |

    How independent are the boards of San Diego's high-tech companies? Lisa Bowman investigates the multiple directors.

    • Lisa Bowman
  • Outlook |

    Kendall Powell finds out how to make those key business connections.

    • Kendall Powell
  • Outlook |

    A tight-knit community and a cooperative spirit has helped San Diego to succeed. Eric Niiler checks out California's rising star.

    • Eric Niiler
  • Outlook |

    San Diego is facing significant challenges to its future development. How do the some of the region's leading lights think it will cope? Ken Howard finds out.

    • Ken Howard
  • Outlook |

    Jonathan Knight takes a look at what the future may hold for innovation in San Diego.

    • Jonathan Knight
  • Outlook |

    A huge number of people have contributed to the success of San Diego. Virginia Gewin catches up with a selection of the region's prime movers.

    • Virginia Gewin
  • Outlook |

    A century of philanthropy alongside military research has laid solid foundations for today's diverse sci-tech sector, says Chloe Veltman.

    • Chloe Veltman